Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.

中文翻译：

---

ISHLT 关于使用耐用、连续流心室辅助装置的患者预防和管理血液相容性相关不良事件策略的共识声明。


拥有耐用、连续流动左心室辅助装置 (CF-LVAD) 的患者的预期寿命持续增加。尽管使用这些设备为患者提供的护理有了显着改善，但与血液相容性相关的不良事件 (HRAE) 仍然令人担忧，并且在发生时会导致显着的发病率和死亡率。因此，传播当前最佳证据和实践至关重要。本 ISHLT 共识声明是对通过口服抗凝剂和抗血小板药物、肠外抗凝药物、HRAE 高危患者和经历血栓或出血事件患者的最佳管理以及设备的最佳管理来预防和管理 HRAE 的当前文献的总结性评估抗血栓药物之外的管理。本文件旨在帮助护理 CF-LVAD 患者的临床医生在预防和管理这些事件方面提供尽可能最好的护理。